• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

卤代罗卡胍衍生物:泛抗肝炎 E 病毒和新兴病毒药物。

Halogenated Rocaglate Derivatives: Pan-antiviral Agents against Hepatitis E Virus and Emerging Viruses.

机构信息

Institute of Organic Chemistry, Leibniz University Hannover, Schneiderberg 1B, 30167 Hannover, Germany.

Department of Molecular and Medical Virology, Ruhr-University Bochum, 44801 Bochum, Germany.

出版信息

J Med Chem. 2024 Jan 11;67(1):289-321. doi: 10.1021/acs.jmedchem.3c01357. Epub 2023 Dec 21.

DOI:10.1021/acs.jmedchem.3c01357
PMID:38127656
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10788925/
Abstract

The synthesis of a library of halogenated rocaglate derivatives belonging to the flavagline class of natural products, of which silvestrol is the most prominent example, is reported. Their antiviral activity and cytotoxicity profile against a wide range of pathogenic viruses, including hepatitis E, Chikungunya, Rift Valley Fever virus and SARS-CoV-2, were determined. The incorporation of halogen substituents at positions 4', 6 and 8 was shown to have a significant effect on the antiviral activity of rocaglates, some of which even showed enhanced activity compared to CR-31-B and silvestrol.

摘要

本文报道了一系列卤代罗卡格莱衍生物的合成,这些化合物属于天然产物 flavagline 类,其中以 silvestrol 最为突出。测定了它们对多种致病病毒(包括戊型肝炎、基孔肯雅热、裂谷热病毒和 SARS-CoV-2)的抗病毒活性和细胞毒性谱。结果表明,在 4'、6 和 8 位引入卤素取代基对罗卡格莱的抗病毒活性有显著影响,其中一些化合物的活性甚至比 CR-31-B 和 silvestrol 更强。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/63f9/10788925/378bba5ea3ea/jm3c01357_0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/63f9/10788925/4979350fcf5e/jm3c01357_0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/63f9/10788925/19d11af71454/jm3c01357_0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/63f9/10788925/3158d8889117/jm3c01357_0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/63f9/10788925/378bba5ea3ea/jm3c01357_0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/63f9/10788925/4979350fcf5e/jm3c01357_0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/63f9/10788925/19d11af71454/jm3c01357_0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/63f9/10788925/3158d8889117/jm3c01357_0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/63f9/10788925/378bba5ea3ea/jm3c01357_0008.jpg

相似文献

1
Halogenated Rocaglate Derivatives: Pan-antiviral Agents against Hepatitis E Virus and Emerging Viruses.卤代罗卡胍衍生物:泛抗肝炎 E 病毒和新兴病毒药物。
J Med Chem. 2024 Jan 11;67(1):289-321. doi: 10.1021/acs.jmedchem.3c01357. Epub 2023 Dec 21.
2
Comparison of broad-spectrum antiviral activities of the synthetic rocaglate CR-31-B (-) and the eIF4A-inhibitor Silvestrol.比较合成的罗卡利特 CR-31-B(-)和 eIF4A 抑制剂西维来司他的广谱抗病毒活性。
Antiviral Res. 2020 Mar;175:104706. doi: 10.1016/j.antiviral.2020.104706. Epub 2020 Jan 10.
3
Natural antiviral compound silvestrol modulates human monocyte-derived macrophages and dendritic cells.天然抗病毒化合物表棓儿醇调节人单核细胞来源的巨噬细胞和树突状细胞。
J Cell Mol Med. 2020 Jun;24(12):6988-6999. doi: 10.1111/jcmm.15360. Epub 2020 May 6.
4
The rocaglate CR-31-B (-) inhibits SARS-CoV-2 replication at non-cytotoxic, low nanomolar concentrations in vitro and ex vivo.罗卡胍 CR-31-B(-)在体外和离体条件下以非细胞毒性、低纳摩尔浓度抑制 SARS-CoV-2 复制。
Antiviral Res. 2021 Feb;186:105012. doi: 10.1016/j.antiviral.2021.105012. Epub 2021 Jan 8.
5
Rocaglates as Antivirals: Comparing the Effects on Viral Resistance, Anti-Coronaviral Activity, RNA-Clamping on eIF4A and Immune Cell Toxicity.罗卡格雷作为抗病毒药物:比较对病毒耐药性、抗冠状病毒活性、eIF4A 上的 RNA 夹闭和免疫细胞毒性的影响。
Viruses. 2022 Mar 3;14(3):519. doi: 10.3390/v14030519.
6
Identification of structurally re-engineered rocaglates as inhibitors against hepatitis E virus replication.鉴定结构重设计的罗格列酮类化合物作为戊型肝炎病毒复制的抑制剂。
Antiviral Res. 2022 Aug;204:105359. doi: 10.1016/j.antiviral.2022.105359. Epub 2022 Jun 18.
7
Inhibition of Hepatitis E Virus Spread by the Natural Compound Silvestrol.天然化合物表没食子儿茶素没食子酸酯抑制戊型肝炎病毒传播。
Viruses. 2018 Jun 2;10(6):301. doi: 10.3390/v10060301.
8
Exploration of (hetero)aryl Derived Thienylchalcones for Antiviral and Anticancer Activities.(杂)芳基衍生的噻吩基查耳酮的抗病毒和抗癌活性研究。
Med Chem. 2019;15(2):150-161. doi: 10.2174/1573406414666180524074648.
9
In-vitro antiviral screening of some thiopyranothiazoles.一些噻吩并噻唑类化合物的体外抗病毒筛选
Chem Biol Interact. 2023 Dec 1;386:110738. doi: 10.1016/j.cbi.2023.110738. Epub 2023 Oct 8.
10
The natural compound silvestrol inhibits hepatitis E virus (HEV) replication in vitro and in vivo.天然化合物表没食子儿茶素没食子酸酯在体外和体内抑制戊型肝炎病毒(HEV)复制。
Antiviral Res. 2018 Sep;157:151-158. doi: 10.1016/j.antiviral.2018.07.010. Epub 2018 Jul 20.

引用本文的文献

1
The continuing need for taxonomic input in phytochemical research.植物化学研究中对分类学投入的持续需求。
J Ethnopharmacol. 2025 Aug 26;354:120474. doi: 10.1016/j.jep.2025.120474.
2
Antiviral Activity of Halogenated Compounds Derived from L-Tyrosine Against SARS-CoV-2.源自L-酪氨酸的卤代化合物对新型冠状病毒的抗病毒活性
Molecules. 2025 Mar 22;30(7):1419. doi: 10.3390/molecules30071419.
3
Discovery of RNA-Protein Molecular Clamps Using Proteome-Wide Stability Assays.利用全蛋白质组稳定性分析发现RNA-蛋白质分子钳

本文引用的文献

1
Identification of structurally re-engineered rocaglates as inhibitors against hepatitis E virus replication.鉴定结构重设计的罗格列酮类化合物作为戊型肝炎病毒复制的抑制剂。
Antiviral Res. 2022 Aug;204:105359. doi: 10.1016/j.antiviral.2022.105359. Epub 2022 Jun 18.
2
Targeting the DEAD-Box RNA Helicase eIF4A with Rocaglates-A Pan-Antiviral Strategy for Minimizing the Impact of Future RNA Virus Pandemics.用罗卡类化合物靶向DEAD盒RNA解旋酶eIF4A——一种将未来RNA病毒大流行影响降至最低的泛抗病毒策略
Microorganisms. 2021 Mar 5;9(3):540. doi: 10.3390/microorganisms9030540.
3
The rocaglate CR-31-B (-) inhibits SARS-CoV-2 replication at non-cytotoxic, low nanomolar concentrations in vitro and ex vivo.
J Proteome Res. 2025 Apr 4;24(4):2026-2039. doi: 10.1021/acs.jproteome.4c01129. Epub 2025 Mar 12.
4
In Vitro Discovery of a Therapeutic Lead for HFMD From a Library Screen of Rocaglates/Aglains.通过对洛卡类化合物/阿格类化合物文库筛选体外发现手足口病治疗先导物。
J Med Virol. 2025 Feb;97(2):e70228. doi: 10.1002/jmv.70228.
5
Amidino-rocaglates (ADRs), a class of synthetic rocaglates, are potent inhibitors of SARS-CoV-2 replication through inhibition of viral protein synthesis.氨甲酰洛沙平类(ADRs)是一类合成的洛沙平类药物,通过抑制病毒蛋白合成,有效抑制了 SARS-CoV-2 的复制。
Antiviral Res. 2024 Oct;230:105976. doi: 10.1016/j.antiviral.2024.105976. Epub 2024 Aug 6.
6
Discovery of RNA-Protein Molecular Clamps Using Proteome-Wide Stability Assays.利用全蛋白质组稳定性分析发现RNA-蛋白质分子钳
bioRxiv. 2024 Dec 21:2024.04.19.590252. doi: 10.1101/2024.04.19.590252.
罗卡胍 CR-31-B(-)在体外和离体条件下以非细胞毒性、低纳摩尔浓度抑制 SARS-CoV-2 复制。
Antiviral Res. 2021 Feb;186:105012. doi: 10.1016/j.antiviral.2021.105012. Epub 2021 Jan 8.
4
Rocaglamide and silvestrol: a long story from anti-tumor to anti-coronavirus compounds.罗卡酰胺和西维来司他:从抗肿瘤化合物到抗冠状病毒化合物的漫长故事。
Nat Prod Rep. 2021 Jan 1;38(1):18-23. doi: 10.1039/d0np00024h. Epub 2020 Jul 23.
5
A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks.一种用于生产高滴度戊型肝炎病毒储备液的细胞培养模型。
J Vis Exp. 2020 Jun 26(160). doi: 10.3791/61373.
6
Design of Development Candidate eFT226, a First in Class Inhibitor of Eukaryotic Initiation Factor 4A RNA Helicase.开发候选药物 eFT226 的设计,一种新型真核起始因子 4A RNA 解旋酶抑制剂。
J Med Chem. 2020 Jun 11;63(11):5879-5955. doi: 10.1021/acs.jmedchem.0c00182. Epub 2020 May 29.
7
Virological assessment of hospitalized patients with COVID-2019.住院 COVID-19 患者的病毒学评估。
Nature. 2020 May;581(7809):465-469. doi: 10.1038/s41586-020-2196-x. Epub 2020 Apr 1.
8
Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR.实时 RT-PCR 检测 2019 新型冠状病毒(2019-nCoV)
Euro Surveill. 2020 Jan;25(3). doi: 10.2807/1560-7917.ES.2020.25.3.2000045.
9
Robust hepatitis E virus infection and transcriptional response in human hepatocytes.在人肝细胞中,戊型肝炎病毒感染具有稳健性和转录反应。
Proc Natl Acad Sci U S A. 2020 Jan 21;117(3):1731-1741. doi: 10.1073/pnas.1912307117. Epub 2020 Jan 2.
10
Amidino-Rocaglates: A Potent Class of eIF4A Inhibitors.氨甲酰基罗卡替丁类药物:一类有效的 eIF4A 抑制剂。
Cell Chem Biol. 2019 Nov 21;26(11):1586-1593.e3. doi: 10.1016/j.chembiol.2019.08.008. Epub 2019 Sep 10.